Results 221 to 230 of about 341,688 (250)
Some of the next articles are maybe not open access.
The fusion inhibitor enfuvirtide in recent antiretroviral strategies
Current Opinion in HIV and AIDS, 2009The purpose of this review is to discuss recent pharmacological, virological, and clinical data that concern enfuvirtide usage in different antiretroviral combinations.Randomized, recent trials in multidrug-experienced patients suggest that antiretroviral combinations with enfuvirtide have excellent virological responses with new antiretroviral ...
Alain, Makinson, Jacques, Reynes
openaire +2 more sources
Novel quinolizidine salicylamide influenza fusion inhibitors
Bioorganic & Medicinal Chemistry Letters, 1999A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 microg/mL in plaque reduction assay.
K L, Yu +11 more
openaire +2 more sources
IDrugs : the investigational drugs journal, 2003
The majority of current antiviral drugs target viral genome replication (eg, reverse transcriptase inhibitors) or virion maturation (eg, protease inhibitors). Although efficient, these drugs suffer from the quick appearance of drug-resistant mutants and usually do not eliminate the virus completely.
openaire +1 more source
The majority of current antiviral drugs target viral genome replication (eg, reverse transcriptase inhibitors) or virion maturation (eg, protease inhibitors). Although efficient, these drugs suffer from the quick appearance of drug-resistant mutants and usually do not eliminate the virus completely.
openaire +1 more source
The introduction of the fusion inhibitors in the HAART-regimens.
The new microbiologica, 2004Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication.
Hasson H +5 more
openaire +2 more sources
[Integrase inhibitor, CCR5 antagonist, fusion inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 2010Integrase inhibitors have a novel antiretroviral mechanism which prevents proviral DNA integration into the CD4+ cell chromosome. Promising results have been seen in clinical trials in treatment-naïve and -experienced infected individuals. CCR5 antagonists bind to CCR5, one of the second receptors of HIV-1, and inhibit HIV-1 entry into CD4+ cells ...
openaire +1 more source
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Frontiers in Oncology, 2022Qian Chu, Jizong Jiang, Jiang Jizong
exaly
Ouabain is a reversible inhibitor of myogenic fusion
In Vitro Cellular & Developmental Biology - Animal, 1994P G, Pauw, G J, Hermann
openaire +2 more sources
Enfuvirtide, an HIV-1 Fusion Inhibitor
New England Journal of Medicine, 2003openaire +2 more sources
ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity
Lung Cancer, 2012Kengo Takeuchi +2 more
exaly